Evaluating the Annual Cost Per Response Rate of Pirfenidone and Nintedanib for the Treatment of Patients With Idiopathic Pulmonary Fibrosis

Value in Health - United Kingdom
doi 10.1016/j.jval.2017.08.1472
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Psy105 - Cost-Utility of Nintedanib Versus Pirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis: A Belgian Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Prs41 - Cost-Effectiveness of Pirfenidone for the Treatment of Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Idiopathic Pulmonary Fibrosis and Pirfenidone

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2010English

Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis

Annals of Thoracic Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2016English

Efficacy of Pirfenidone in Patients With Advanced-Stage Idiopathic Pulmonary Fibrosis

Internal Medicine
Internal MedicineMedicine
2013English

Efficacy and Safety of Nintedanib in Patients With Advanced Idiopathic Pulmonary Fibrosis

BMC Pulmonary Medicine
PulmonaryRespiratory Medicine
2020English

Pirfenidone Should Be Prescribed for Patients With Idiopathic Pulmonary Fibrosis: Table 1

Thorax
PulmonaryRespiratory Medicine
2013English

Pirfenidone Treatment in Idiopathic Pulmonary Fibrosis: Nationwide Danish Results

European Clinical Respiratory Journal
2016English

Remarkable Improvement in a Patient With Idiopathic Pulmonary Fibrosis After Treatment With Nintedanib

Internal Medicine
Internal MedicineMedicine
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy